Sales gap grows between rival Merck, Bristol cancer therapies

Keytruda posted $2.6 billion in sales during the second quarter, spurring Merck to substantially boost its revenue projections for the year.

By Ned Pagliarulo • July 30, 2019

FTC probing J&J on Remicade, as biosimilar market remains muted

The anti-inflammation drug has held onto its market share despite years of biosimilar competition. Now, the FTC wants to know how.

By Andrew Dunn • July 30, 2019

Explore the Trendline➔

Commercialization

New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.

By BioPharma Dive staff

European regulators back Bayer, GW drugs, but with caveats

The CHMP recommended conditional approval of Vitrakvi while also advising Epidiolex be used as adjunctive therapy, an opinion one analyst described as "disappointing."

By Jacob Bell • July 26, 2019

FDA warns cannabis company for illegal marketing of CBD products

At issue are "unsubstantiated claims" made by Curaleaf about the health benefit of its cannabidiol products. 

By Kristin Jensen • July 24, 2019

Advocacy group pledges six-figure ad buy to support Trump drug price plan

Patients for Affordable Drugs relaunched a campaign which supports the Trump administration's proposed International Pricing Index for certain drugs.

By Jonathan Gardner • July 17, 2019

Weathering the privacy storm

How to stay above water in the changing digital marketing landscape.

July 16, 2019

Xarelto falls into the donut hole

A 19% decline from 2018 sales was a dark cloud in an otherwise mostly positive quarterly earnings for Johnson & Johnson.

By Jonathan Gardner • July 16, 2019

ICER unconvinced peanut allergy drugs are better than just avoiding the food

The influential cost watchdog group argues that treatments from DBV and Aimmune haven't shown long-term benefits — or, more broadly, quality-of-life improvements.

By Jacob Bell • July 11, 2019

Billion-dollar settlement gets Reckitt out of federal opioid probes

Company spinout Indivior, however, is still facing criminal charges related to marketing of Suboxone film, an opioid dependence treatment. 

By Jonathan Gardner • July 11, 2019

New GSK data raises threat to Gilead's star HIV drug

Dovato, GSK's two-drug HIV treatment, maintained viral suppression about as well as three-drug regimens with a similar makeup to Gilead's Biktarvy.

By Jacob Bell • July 10, 2019

In win for pharma, Trump TV drug price rule struck down

The federal district court sided with drugmakers, which argued the government overstepped its authority in forcing price transparency in advertisements.

By Jonathan Gardner • July 9, 2019

UK testing Netflix-style payments to boost antibiotics development

Officials hope the model will overcome some of the obstacles that have stifled the commercial prospects for new antibiotics.

By Jacob Bell • July 9, 2019

BioMarin confirms timeline for hemophilia gene therapy, putting pressure on rivals

The biotech plans on submitting valrox to U.S. and European regulators in the fourth quarter, which could bring approval decisions by mid-2020.

By Jacob Bell • July 8, 2019

Zolgensma set a new drug pricing bar. Insurers show some signs of pushback

One month after approval, a handful of payers have adopted policies taking a more cautious stance than what the FDA set out in the gene therapy's label.

By Ned Pagliarulo • Updated July 5, 2019

BioPharma Dive's 10 biggest stories of the spring

Developments in gene therapy, cancer treatments, drug pricing and dealmaking kept the industry in the headlines.

By Jacob Bell • July 3, 2019

Amarin to double sales team again as it boosts Vascepa sales forecast

The drugmaker also plans to start direct-to-consumer advertising in the second quarter of next year, aiming to further grow sales of the fish oil pill.

By Andrew Dunn • July 2, 2019

A spotlight on patient-provider dialogue

Patient-provider dialogue is a critical part of your brand’s success. Start giving it the attention it deserves.

July 2, 2019

Aiming for price transparency, Civica Rx hits snag with bundled payments

The payment model, often opaque on specific drug costs, affects many of the medicines the hospital-led group is targeting, according to its commercial chief.

By Jacob Bell • June 27, 2019

CMS approves Louisiana's 'Netflix model' using Gilead hepatitis C drugs

The subscription model will go into effect Monday, and a similar plan by Washington state is also expected to start next week.

By Rebecca Pifer Parduhn • June 26, 2019

Samsung Bioepis CEO urges patience as US biosimilar market lags

"Market shaping takes time," the head of the Korean drugmaker told BioPharma Dive, as a few experts call to give up on the copycat biologics altogether. 

By Ned Pagliarulo • June 26, 2019

Pharmacquired: Is $11B enough to secure Sanofi's spot in hemophilia?

Gene therapies and other long-acting treatments are threatening to outdate the drugs Sanofi got from its Bioverativ deal.

By Jacob Bell • June 19, 2019

Upadacitinib a plus for AbbVie in rheumatoid arthritis, doc survey says

A Piper Jaffray survey of physicians suggests the new drug won't cannibalize Humira, but instead take market share from Olumiant and Xeljanz.

By Jonathan Gardner • June 14, 2019

Allergan reportedly hires Spark Foundry as US advertising agency

The new media agency will come on board as Allergan attempts to mount a turnaround, facing discontent from investors.

By Kristin Jensen • June 12, 2019

Influential task force urges payers to cover PrEP for HIV

The recommendation from the U.S. Preventive Services Task Force could expand access to Gilead's Truvada, which has come under scrutiny for its cost. 

By Samantha Liss • June 12, 2019

How pharma can drive value and embrace change in an evolving marketplace

Pharma sales organizations need to adapt to today's evolving healthcare marketplace.

June 11, 2019